Table 1.
Clinical, peripheral blood and bone marrow features of myelodysplastic/ myeloproliferative neoplasms-unclassifiable (MDS/MPN-U) with i(17q) [study group) with MDS/MPN-U cases without isolated i(17q) [ control group].
| MDS/MPN-U with iso i(17q) n = 29 |
MDS/MPN-U without i(17q) n = 63 |
P | |
|---|---|---|---|
| Age yr (median, range) | 67 (41–88) | 71 (60–88) | .005 |
| Male gender | 13 (45%) | 33 (52%) | NS |
| Splenomegaly (frequency) | 20 (69%) | 8 (16%) | .001 |
| Peripheral blood (PB) counts | |||
| Hemoglobin | 9.4 (5.8–15.1) | 10.1 (6.8–13.6) | .037 |
| White Blood Cell counts | 13.6 (1.2–119) | 19.4 (1.5–98.7) | NS |
| Platelet count x 109/L (median, range) | 103 (16–1000) | 142 (11–1040) | NS |
| ANC x 109/L (median, range) | 4.6 (0.3–50) | 15.8 (0.74–79.9) | .008 |
| PB blasts (median, range) | 2 (0–13) | 0 (0–13) | .057 |
| Bone marrow (BM) morphologic features | |||
| BM blasts% (median, range) | 4 (0–18) | 2 (0–17) | NS |
| Dyserythropoiesis | 9/22 (41%) | 29/57 (51%) | NS |
| Dysgranulopoiesis | 13/22 (59) | 38/58 (66%) | NS |
| Dysmegakaryopoiesis | 22/22 (100%) | 41/56 (73%) | .008 |
| Myelofibrosis (MF) grade 2/3 | 9/22 (41%) | 15/57 (26%) | NS |
| Treatment data | n=28 | n=58 | |
| Supportive | 7 (25%) | 12 (21%) | NS |
| Chemotherapy only | 3 (11%) | 5 (9%) | NS |
| Hypomethylating agents (HMA) | 13 (47%) | 25 (43%) | NS |
| HMA plus chemotherapy/ others | 3 (11%) | 9 (14%) | NS |
| Others* | 2 (7%) | 3 (5%) | NS |
| Allogeneic stem cell transplant | 6 of 28 (21%) | 5 of 58 (9%) | NS |
ANC, Absolute Neutrophil Count; PB, peripheral blood; BM, bone marrow